by Stefan Ravello | Jun 11, 2026 | Hematology-Oncology, Multiple Myeloma
As the treatment landscape for multiple myeloma evolves, emerging Cereblon E3 ligase modulators (CELMoDs) are poised to redefine how clinicians approach relapsed/refractory disease. This course examines how iberdomide and mezigdomide differ from traditional IMiDs...
by Stefan Ravello | May 11, 2026 | Oncology, PARP-Combination Therapy, Prostate Cancer
Prostate cancer is the most common solid cancer in men worldwide. Most men are diagnosed as having localized disease because of the widespread use of prostate-specific antigen screening. Men diagnosed as having clinically localized prostate cancer have multiple...
by Stefan Ravello | May 11, 2026 | Breast Cancer, Oncology
Early-stage hormone receptor-positive, HER2-negative (HR+/HER2−) breast cancer is the most common breast cancer subtype, accounting for roughly two-thirds to three-quarters of all new breast cancer cases in the United States (U.S.). Endocrine therapy (ET) has long...
by Stefan Ravello | May 11, 2026 | Hematology-Oncology, Multiple Myeloma
Multiple myeloma (MM) is a malignant plasma cell disorder and the second most common blood cancer in the United States (U.S.) Survival has improved markedly with modern therapies – the 5-year survival rate has more than doubled in recent decades – yet myeloma remains...
by Stefan Ravello | Feb 11, 2026 | Neurology
The recent development and approval of blood-based biomarker tests (BBMs) for detecting neuropathologic changes associated with Alzheimer’s disease (AD) can enhance the care of patients by facilitating earlier diagnosis in both primary care and specialty settings....
